Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Farmaci Expressen ME AB
AB
Active
Org 5592476468
Vibblabyvägen 10
General medical practice activities · NACE 8621
Est. 2020
1 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
SEK 644K
-18% vs 2024
EBITDA margin
32.8%
+14% vs 2024
Equity ratio
45.6%
Financial strength
Net profit 2025
SEK 125K
-15% vs 2024
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
SEK 644K
-18%
EBITDA
SEK 211K
+14%
Net profit
SEK 125K
-15%
Total assets
SEK 438K
-10%
Equity
SEK 200K
-35%
Employees
1
—
Company information
Legal name
Farmaci Expressen ME AB
Org number
5592476468
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
12 mars 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Konsultverksamhet för farmaceuter. Uppdragen innefattar allt från tjänster i läkemedelsföretag till arbete på apotek.
Contact
Address
Vibblabyvägen 10
Email
mohammedelhassan692@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in General medical practice activities
Companies in Sigtuna
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
1M
2021
1M
2022
1M
2023
1M
2024
1M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
0M
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
704
776
701
789
644
Staff expenses
—
−498
−336
−401
−274
EBITDA
485
245
265
185
211
Depreciation & amort.
−0
−35
—
—
—
EBIT
485
210
265
185
211
Net financials
—
−0
−2
−1
−2
Profit before tax
485
210
263
184
157
Tax
−100
−44
−54
−38
−32
Net profit
385
166
209
146
125
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
779
530
492
486
438
Equity
410
284
324
305
200
Long-term debt
0
—
—
—
—
Short-term debt
369
246
168
181
186
Total debt
369
246
168
181
186
Financial ratios
5-year trend
EBITDA margin
32.8%
This company
15.8%
Market median
+108% vs market
2021
2025
Equity ratio
45.6%
This company
38.2%
Market median
+19% vs market
2021
2025
Return on equity
62.5%
This company
18.4%
Market median
+240% vs market
2021
2025
Net profit margin
19.4%
This company
8.1%
Market median
+140% vs market
2021
2025
Asset turnover
1.47×
This company
1.12×
Market median
+31% vs market
2021
2025
Debt / equity
1.19×
This company
0.62×
Market median
-92% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
ME
Mohamed Elhassan
Chief Executive Officer
Chief Executive Officer
2022
Board of directors
Non-executive oversight
Name
Role
Member since
Current (1)
HA
Hind Abouhachem
Deputy Board Member
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Farmaci Expressen ME AB also hold positions in
0
other companies.
Person
Role here
Other companies
Mohamed Elhassan
Chief Executive Officer
0 companies
Hind Abouhachem
Deputy Board Member
0 companies